Thread by @ee_schenberg

This week #psychedelics, almost completely ignored by western science and medicine in the last quarter of the 20th century, made it to the top of 🇺🇸 healthcare, the @NIH:

4k folks 🌐 21 time zones
+10h of talks
Panelists from
🇺🇸 12
🇨🇦 1
🇮🇱 1
🇩🇰 1
🇬🇧 1
🇳🇿 1
🇨🇭 1

🧵 summary 👇

Agenda comprised 3 main themes:
Basic and translational research 🐀🔬👩‍🔬👨‍🔬🧮💻
Clinical trials 👩‍⚕️🧑‍⚕️👨‍⚕️🤮💊🤒💉
Optimising future trial designs 💾💽💿📀

Here are my remarks from 20y experience:
This is a good landmark to claim psychedelic science finally achieved maturity
Basic research is evolving rapidly and public funding 💰is what is needed to transform the field
Clinical trials suggest transdiagnostic safety and efficacy

Here are some BIG controversies:
Should only 5HT2A agonists be classified “psychedelics”?
Should this name be kept, changed, refined?
Are subjective effects necessary or nuisance?
How to better blind participants to deal with expectancy and disappointment?
Which model is best?

If you want to know more, you can check my 3 live threads 🤓 below
threadreaderapp.com/thread/1481265…
threadreaderapp.com/thread/1481636…
threadreaderapp.com/thread/1481681…